SK Biopharm's 'Cenobamate' Enters Canada... "Technology Export to Endo Group"

From the US to Canada... "North American Market Entry Completed"

[Image source=Yonhap News]

[Asia Economy Reporter Kim Daehyun] SK Biopharm has licensed its innovative epilepsy drug 'Cenobamate' to Endo Group to complete its entry into the North American market.

On the morning of the 23rd, SK Biopharm announced that it had licensed Cenobamate to Endo Group for commercialization in Canada. SK Biopharm will receive an upfront payment of 20 million USD (approximately 23.8 billion KRW) and royalties of 21 million CAD (approximately 19.4 billion KRW) upon regulatory approval and commercialization. Additional profits from Cenobamate supply will also be secured.

Previously, Cenobamate received approval from the U.S. Food and Drug Administration (FDA) in November 2019 and began sales in the U.S. the following year through its local subsidiary SK Life Science. With this partnership with Endo Group, SK Biopharm has expanded its reach to Canada, completing its entry into the North American market.

The launch will be handled by Paladin Labs, a Canadian pharmaceutical company and subsidiary of Endo Group. Endo Group is a healthcare-focused global company headquartered in Ireland, with business sectors including innovative drugs, generics, medical devices, and aesthetic products.

Jungwoo Cho, CEO of SK Biopharm, said, "We are pleased to form a strategic alliance with Endo Group to enter the Canadian market," adding, "We will continue to expand partnerships with local pharmaceutical companies to ensure Cenobamate is prescribed globally."

This content was produced with the assistance of AI translation services.